In a small study of 170 women with invasive estrogen receptor–positive breast cancer, who were treated with either anastrozole for 12 weeks followed by letrozole (or the reverse) and who were subsequently switched to tamoxifen, joint pain was reported by 76% while on an AI, and no difference between the two AIS was observed 43. The gene discussed is ESR1; the disease is breast carcinoma.